Philip Urban

Philip Urban

Auto-generated profile, based on publicly available information

Philip Urban

Hôpital de la Tour, Geneva, Switzerland (P.U.).

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Circulation
Verified
Journal Article
Closed access
Felice GragnanoFelice Gragnano
Felice Gragnano
DKDavid van Klaveren
David van Klaveren
DHDik Heg
Dik Heg
LRLorenz Räber
Lorenz Räber
MKMitchell W. Krucoff
Mitchell W. Krucoff
MVMarco Valgimigli
Marco Valgimigli
BACKGROUND: Accurate bleeding risk stratification after percutaneous coronary intervention is important for treatment individualization. However, there is still an unmet need for a more precise and standardized identification of patients at high bleeding risk. We derived and validated a novel bleeding risk score by augmenting the Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE-DAPT) score with the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria. METHODS: The derivation cohort comprised 29 188 patients undergoing percutaneous coronary intervention, of whom 1136 (3.9%) had Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding at 1 year, from 4 contemporary real-world registries and the XIENCE V USA trial. The PRECISE-DAPT score was refitted with a Fine-Gray model in the derivation cohort and extended with the ARC-HBR criteria. The primary outcome was BARC 3 or 5 bleeding within 1 year. Independent predictors of BARC 3 or 5 bleeding were selected at multivariable analysis ( P <0.01). The discrimination of the score was internally assessed with apparent validation and cross-validation. The score was externally validated in 4578 patients from the MASTER DAPT trial (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen) and 5970 patients from the STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy-2) total cohort. RESULTS: The PRECISE-HBR score (age, estimated glomerular filtration rate, hemoglobin, white blood cell count, previous bleeding, oral anticoagulation, and ARC-HBR criteria) showed an area under the curve (AUC) for 1-year BARC 3 or 5 bleeding of 0.73 (95% CI, 0.71–0.74) at apparent validation, 0.72 (95% CI, 0.70–0.73) at cross-validation, 0.74 (95% CI, 0.68–0.80) in MASTER DAPT, and 0.73 (95% CI, 0.66–0.79) in STOPDAPT-2, with superior discrimination compared with PRECISE-DAPT (cross-validation: ΔAUC, 0.01; P =0.02; MASTER DAPT: ΔAUC, 0.05; P =0.004; STOPDAPT-2: ΔAUC, 0.02; P =0.20) and other risk scores. In the derivation cohort, a cutoff of 23 points identified 11 414 patients (39.1%) with a 1-year BARC 3 or 5 bleeding risk ≥4%. An alternative version of the score, including acute myocardial infarction on admission instead of white blood cell count, showed similar predictive ability. CONCLUSIONS: The PRECISE-HBR score is a contemporary, simple 7-item risk score to predict bleeding after percutaneous coronary intervention, offering a moderate improvement in discrimination over multiple existing scores. Further evaluation is required to assess its impact on clinical practice.

15 June 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ASAlessandro Spirito
Alessandro Spirito
Felice GragnanoFelice Gragnano
Felice Gragnano
NCNoé Corpataux
Noé Corpataux
LVLukas Vaisnora
Lukas Vaisnora
Roberto GaleaRoberto Galea
Roberto Galea
MVMarco Valgimigli
Marco Valgimigli
Background: Female sex was not included among the high bleeding risk (HBR) criteria by the Academic Research Consortium (ARC) as it remains unclear whether it constitutes an HBR condition after percutaneous coronary intervention. We investigated whether female sex associates with HBR and assessed the performance of ARC HBR criteria separately in women and men. Methods and Results: Among all consecutive patients undergoing percutaneous coronary intervention between 2009 and 2018, bleeding occurrences up to 1 year were prospectively collected and centrally adjudicated. All but one of the originally defined ARC HBR criteria were assessed, and the ARC HBR score generated accordingly. Among 16 821 patients, 25.6% were women. Compared with men, women were older and had lower creatinine clearance and hemoglobin values. After adjustment, female sex was independently associated with access‐site (adjusted hazard ratio, 2.14; 95% CI, 1.22–3.74; P =0.008) but not with overall or non–access‐site 1‐year Bleeding Academic Research Consortium 3 or 5 bleeding. This association remained consistent when the femoral but not the radial approach was chosen. The ARC HBR score discrimination, using the original criteria, was lower among women than men (c‐index 0.644 versus 0.688; P =0.048), whereas a revised ARC HBR score, in which age, creatinine clearance, and hemoglobin were modeled as continuous rather than dichotomized variables, performed similarly in both sexes. Conclusions: Female sex is an independent predictor for access‐site bleeding but not for overall bleeding events at 1 year after percutaneous coronary intervention. The ARC HBR framework shows an overall good performance in both sexes, yet is lower in women than men, attributable to dichotomization of age, creatinine clearance, and hemoglobin values, which are differently distributed between sexes. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02241291.

1 February 1995 in Catheterization and Cardiovascular Diagnosis
Verified
Journal Article
Closed access
PDF file
VMVivek K. Mehan
Vivek K. Mehan
UKUrs Kaufmann
Urs Kaufmann
PUPhilip Urban
Philip Urban
PCPascal Chatelain
Pascal Chatelain
BMBernhard Meier
Bernhard Meier

1 March 2003 in Heart Drug
Verified
Journal Article
Closed access
PDF file
PEPaul Erne
Paul Erne
DRDragana Radovanovic
Dragana Radovanovic
PUPhilip Urban
Philip Urban
JSJean-Christophe Stauffer
Jean-Christophe Stauffer
OBOsmund Bertel
Osmund Bertel
FGFelix Gutzwiller
Felix Gutzwiller
Background: Early drug therapy in patients with ST-elevation infarction is essential for improved short- and long-term outcomes. Most of the drugs used currently have been extensively studied in the era prior to reperfusion therapies, and thus it is important to assess the value of these drugs in today’s clinical practice and compare the results with those of randomized trials. Objectives: The study assessed the effects of age, gender, risk factors, reperfusion therapy and early drug therapy in patients with acute myocardial infarction with ST elevation or new left bundle-branch block on in-hospital mortality. Methods: The analysis of drug administration and in-hospital mortality is based on the AMIS Plus project, a registry of acute coronary syndromes in Switzerland since 1997. Data from 7,279 patients admitted to participating hospitals between 1997 and 2002 were analyzed, and the effect of factors and drug therapies on in-hospital mortality was assessed by logistic regression analysis. Results: Age and diabetes were identified as factors associated with a higher likelihood of in-hospital mortality, while a significant and important reduction of in-hospital mortality was due to the use of thrombolytic therapy or primary percutaneous coronary intervention (PCI) [relative risk reduction (RRR) of 31%, odds ratio (OR) and 95% confidence interval: 0.69; 0.54–0.87; p = 0.002 for thrombolysis, RRR of 34%; OR 0.66; 0.44–0.99; p = 0.044 for PCI]. Early administration of aspirin or ADP antagonists is associated with a risk reduction of in-hospital mortality by 36% (OR 0.63; 0.45–0.89; p = 0.009) and 50% (OR 0.49; 0.35–0.70; p < 0.001), respectively. The use of unfractionated heparin did not reduce in-hospital mortality. Administration of ACE inhibitors, nitrates or beta-blockers reduced the relative risk of in-hospital death by 40% (OR 0.60; 0.49–0.75; p = 0.009), 42% (OR 0.58; 0.46–0.72; p < 0.001) and 54% (OR 0.46; 0.37–0.57; p < 0.001), respectively. Less frequent use of reperfusion therapies and beta-blockers was documented for older patients. Gender was not a determining factor for in-hospital survival. Conclusion: Early administration of aspirin or ADP inhibition with ticlopidine or clopidogrel as well as the early use of beta-blockers, nitrates and ACE inhibitors had a beneficial effect on in-hospital mortality in the reperfusion era with either thrombolytics or PCI. The association of a beneficial effect of ADP inhibition was more pronounced than that found in randomized trials for non-ST-elevation infarction. However, it cannot be excluded that patients with a lower risk for in-hospital death who were selected for early invasive assessment received more frequently ADP inhibitors and that this influenced this beneficial effect. Diabetes and age had negative effects on in-hospital mortality, and both reperfusion therapy and beta-blockers were much less frequently used in elderly patients.

1 August 2007 in EuroIntervention
Verified
Journal Article
Closed access
DBDidier Blanchard
Didier Blanchard
GDGian Battista Danzi
Gian Battista Danzi
PUPhilip Urban
Philip Urban
MMMorris Moseri
Morris Moseri
CJCraig Juergens
Craig Juergens
DPDragica Paunovic
Dragica Paunovic
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

21 May 2020 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
GRGert Richardt
Gert Richardt
MAMohammad Abdelghani
Mohammad Abdelghani
AAAbdelhakim Allali
Abdelhakim Allali
RTRalph Toelg
Ralph Toelg
MAMohamed Abdellaoui
Mohamed Abdellaoui
PUPhilip Urban
Philip Urban